Nutra Pharma Corp Stock Performance
| NPHC Stock | USD 0.0001 0.00 0.00% |
Nutra Pharma holds a performance score of 34 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 3.6, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nutra Pharma will likely underperform. Use Nutra Pharma Corp coefficient of variation and the relationship between the information ratio and day median price , to analyze future returns on Nutra Pharma Corp.
Risk-Adjusted Performance
34 of 100
Weak | Strong |
Very Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Nutra Pharma Corp are ranked lower than 34 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak technical indicators, Nutra Pharma exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | -293.5 K |
Nutra |
Nutra Pharma Relative Risk vs. Return Landscape
If you would invest 0.01 in Nutra Pharma Corp on August 31, 2024 and sell it today you would earn a total of 0.00 from holding Nutra Pharma Corp or generate 0.0% return on investment over 90 days. Nutra Pharma Corp is currently generating 192.8571% in daily expected returns and assumes 439.3427% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Nutra, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nutra Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nutra Pharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Nutra Pharma Corp, and traders can use it to determine the average amount a Nutra Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.439
| Best Portfolio | Best Equity | NPHC | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 439.34 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.44 actual daily | 34 66% of assets perform better |
Based on monthly moving average Nutra Pharma is performing at about 34% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nutra Pharma by adding it to a well-diversified portfolio.
Nutra Pharma Fundamentals Growth
Nutra Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Nutra Pharma, and Nutra Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nutra Pink Sheet performance.
| Return On Asset | -1.13 | |||
| Profit Margin | 28.71 % | |||
| Operating Margin | (5.58) % | |||
| Current Valuation | 10.33 M | |||
| Shares Outstanding | 7.6 B | |||
| Price To Sales | 6.13 X | |||
| Revenue | 51.9 K | |||
| EBITDA | (365.66 K) | |||
| Cash And Equivalents | 10.45 K | |||
| Total Debt | 517.18 K | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (878.09 K) | |||
| Total Asset | 301.79 K | |||
About Nutra Pharma Performance
By analyzing Nutra Pharma's fundamental ratios, stakeholders can gain valuable insights into Nutra Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Nutra Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Nutra Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company was incorporated in 2000 and is based in Plantation, Florida. NUTRA PHARMA operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Nutra Pharma Corp performance evaluation
Checking the ongoing alerts about Nutra Pharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Nutra Pharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nutra Pharma Corp is not yet fully synchronised with the market data | |
| Nutra Pharma Corp is way too risky over 90 days horizon | |
| Nutra Pharma Corp has some characteristics of a very speculative penny stock | |
| Nutra Pharma Corp appears to be risky and price may revert if volatility continues | |
| Nutra is showing solid risk-adjusted performance over 90 days | |
| Nutra Pharma Corp currently holds 517.18 K in liabilities. Nutra Pharma Corp has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nutra Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nutra Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nutra Pharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nutra to invest in growth at high rates of return. When we think about Nutra Pharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 51.9 K. Net Loss for the year was (769.18 K) with profit before overhead, payroll, taxes, and interest of 8.47 K. | |
| Nutra Pharma Corp currently holds about 10.45 K in cash with (878.09 K) of positive cash flow from operations. |
- Analyzing Nutra Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nutra Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Nutra Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nutra Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nutra Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nutra Pharma's pink sheet. These opinions can provide insight into Nutra Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Nutra Pink Sheet analysis
When running Nutra Pharma's price analysis, check to measure Nutra Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nutra Pharma is operating at the current time. Most of Nutra Pharma's value examination focuses on studying past and present price action to predict the probability of Nutra Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nutra Pharma's price. Additionally, you may evaluate how the addition of Nutra Pharma to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |